The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

We recently published a list of Jim Cramer’s February Portfolio: Top 10 Stocks. In this article, we are going to take a look ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...